7.87
Karyopharm Therapeutics Inc Aktie (KPTI) Neueste Nachrichten
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
MACD Signal: Why Karyopharm Therapeutics Inc stock attracts global investors2025 Winners & Losers & Safe Capital Growth Tips - moha.gov.vn
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
KPTI (Karyopharm Therapeutics Inc) has impressive results - uspostnews.com
Karyopharm Therapeutics (FRA:25K0) EV-to-OCF : -2.79 (As of Dec. 22, 2025) - GuruFocus
Why Karyopharm Therapeutics Inc. (25K0) stock could be next leader2025 Earnings Impact & Growth Focused Investment Plans - Улправда
Can Karyopharm Therapeutics Inc. stock resist sector downturnsJuly 2025 Market Mood & High Accuracy Trade Alerts - Улправда
Is Karyopharm Therapeutics Inc. stock a bargain at current levelsIndustrial Stocks Review & Free Extraordinary Earning Power - bollywoodhelpline.com
How Karyopharm Therapeutics Inc. stock responds to policy changesWeekly Trend Summary & Fast Entry Momentum Alerts - DonanımHaber
Can Karyopharm Therapeutics Inc. stock withstand economic slowdownJuly 2025 Gainers & Precise Swing Trade Entry Alerts - DonanımHaber
Will Karyopharm Therapeutics Inc. stock remain a Wall Street favoriteMarket Activity Recap & Weekly Return Optimization Plans - Улправда
Is Karyopharm Therapeutics Inc. stock attractive for income investors2025 Earnings Impact & Fast Gain Stock Tips - DonanımHaber
Will Karyopharm Therapeutics Inc. (25K0) stock beat international competitionQuarterly Portfolio Review & Accurate Entry/Exit Alerts - Улправда
Piper Sandler names Karyopharm stock as 2026 top pick, maintains $12 target - Investing.com Canada
Karyopharm Therapeutics’ Earnings Call: Progress Amid Challenges - MSN
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Above 50-Day Moving AverageHere's What Happened - MarketBeat
Karyopharm to Participate in Baird's Biotech Discovery Series - Karyopharm
Karyopharm (Nasdaq: KPTI) to discuss myelofibrosis in Baird Biotech Discovery Series chat - Stock Titan
Published on: 2025-12-10 09:05:07 - earlytimes.in
Karyopharm Therapeutics (KPTI) Price Target Decreased by 11.70% to 14.11 - MSN
Is Karyopharm Therapeutics Inc. (25K0) stock among top earnings plays2025 Technical Overview & Safe Capital Growth Tips - Newser
How Karyopharm Therapeutics Inc. (25K0) stock reacts to new regulationsTrade Volume Summary & Daily Stock Trend Watchlist - Newser
What makes Karyopharm Therapeutics Inc. (25K0) stock appealing to growth investorsJuly 2025 Volume & Fast Exit and Entry Strategy Plans - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock outperform global peersJuly 2025 PostEarnings & Real-Time Buy Zone Alerts - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock split increase liquidity2025 Big Picture & Fast Gaining Stock Reports - Newser
Will Karyopharm Therapeutics Inc. (25K0) stock announce special dividendMarket Growth Summary & Expert Curated Trade Ideas - Newser
Why global investors buy Karyopharm Therapeutics Inc. (25K0) stockJuly 2025 Highlights & AI Based Buy/Sell Signal Reports - Newser
Karyopharm Therapeutics (KPTI) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Karyopharm (Nasdaq: KPTI) plans fireside chat at Piper Sandler 37th Healthcare Conference - Stock Titan
Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference - Karyopharm
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Looking at the Narrative for Karyopharm as Financing and Trial Milestones Shift the Outlook - Yahoo Finance
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Below 200 Day Moving AverageWhat's Next? - MarketBeat
[424B3] Karyopharm Therapeutics Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Is Karyopharm Therapeutics Inc. stock vulnerable to regulatory risks2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Why Karyopharm Therapeutics Inc. (25K0) stock trades below fair valueJuly 2025 Opening Moves & Detailed Earnings Play Strategies - newser.com
How Karyopharm Therapeutics Inc. stock reacts to job market dataStock Surge & AI Driven Price Predictions - newser.com
Is Karyopharm Therapeutics Inc. (25K0) stock undervalued by metrics2025 Investor Takeaways & Daily Stock Trend Watchlist - newser.com
What momentum indicators show for Karyopharm Therapeutics Inc. stockJuly 2025 Reactions & Consistent Income Trade Recommendations - newser.com
Why pension funds invest in Karyopharm Therapeutics Inc. (25K0) stockRate Cut & Technical Pattern Recognition Alerts - newser.com
Can Karyopharm Therapeutics Inc. stock hit record highs againGold Moves & AI Driven Stock Movement Reports - newser.com
Is Karyopharm Therapeutics Inc. stock attractive for long term wealth building2025 Short Interest & Consistent Profit Alerts - newser.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):